InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

InMed Pharmaceuticals Inc., a leader in the research, development and manufacturing of rare cannabinoids, announces it is supporting initiatives to raise awareness of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Epidermolysis Bullosa Global Awareness Week is October 25-31, 2022...READ MORE

Canary Medical Announces Appointment of Lisa Suennen as President, Digital and Data Solutions

Canary Medical, a medical data company focused on the development and commercialization of its patented implantable sensor technology and data management ecosystem, announced the appointment of Lisa Suennen as President, Digital and Data Solutions. Ms. Suennen previously served as the Group Practice Lead for Manatt Phelps and Philips’ Digital and Technology Group and Managing Partner for the Manatt Venture Fund...READ MORE

U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody...READ MORE

Algernon Pharmaceuticals Enters Into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that it has entered an Investigator-Initiated Clinical Trial Agreement with Yale University for the investigation of multiple intravenous doses of DMT for the treatment of depression. The trial’s principal investigator is Professor Deepak Cyril D’Souza, an experienced researcher with DMT and other controlled substances...READ MORE

Breztri™ Aerosphere® now Available in Canada for Long-Term Maintenance Treatment of COPD

AstraZeneca announced the Canadian availability of Breztri™ Aerosphere® (budesonide/glycopyrronium/formoterol fumarate dihydrate), indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA...READ MORE

Roche Receives FDA Clearance for COVID-19 PCR Test for use on Cobas 6800/8800 Systems

Roche announced that the U.S. FDA has granted 510(k) clearance for the cobas® SARS-CoV-2 Qualitative PCR test for use on the fully automated cobas® 6800 and cobas® 8800 Systems. This standalone test is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasal and nasopharyngeal samples from symptomatic patients who are suspected of having COVID-19 as determined by their healthcare provider...READ MORE

Sernova Corp. Announces Change of Auditor

Sernova’s board of directors appointed the Successor Auditor, KPMG LLP, to hold office as the new auditor of the Corporation until the close of the Corporation’s next annual general meeting of shareholders. The Corporation’s former auditor, Davidson & Company, Chartered Professional Accountants, resigned effective October 14, 2022, at the request of Sernova...READ MORE

RINVOQ® (Upadacitinib) Receives its Sixth U.S. FDA Approval

AbbVie announced the U.S. FDA has approved RINVOQ^® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy. This additional indication follows the FDA approval of RINVOQ in April of this year for adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers, making it the first and only JAK inhibitor that is approved for both conditions...READ MORE

Lumira Ventures Participates in the Closing of PIC Therapeutics $35 Million Series a Financing to Develop Treatments for Drug-Resistant Breast Cancer

PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, announced the closing of a $35 million Series A financing led by OrbiMed. Other new investors participating in this financing include Lumira Ventures and Harrington Discovery Institute. The company’s existing investors including Advent Life Sciences and Belinda Termeer also participated and provided initial seed financing instrumental to meeting key milestones...READ MORE

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) Officially Opens Charlottetown Biomanufacturing Training Facility

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) today officially opened their new CASTL Biomanufacturing Training Facility located in Charlottetown, Prince Edward Island. The new training facility contains state-of-the-art pilot-scale bioprocessing equipment that will allow employees to gain practical skills that are immediately transferable to process scale-up and clean room environments...READ MORE

New Cancer Imaging and Treatment Starts Soon in Nova Scotia

Nova Scotia will be the first place in Canada to use the equipment called Ethos, made by California-based Varian Medical Systems. It’s already been installed at the QEII Hospital in Halifax where clinical trials are expected to begin within weeks....READ MORE

Drone Delivery Project Will Deliver Medical Isotopes

McMaster University is partnering with Halton Healthcare, Drone Delivery Canada (DDC), Air Canada Cargo and DSV Canada to develop a drone delivery system that will revolutionize how medical goods – including medical isotopes made at McMaster – reach hospitals and patients across Halton Region...READ MORE

Ontario Announces Three More Health Teams

The Ontario government, in partnership with Ontario Health, has approved three new Health Teams in Northern Ontario that will break down barriers in people’s healthcare to provide connected and more convenient care...READ MORE

Minister Ng Announces New Venture Capital Investments

The Honourable Mary Ng, Minister of International Trade, Export Promotion, Small Business and Economic Development, announced that up to $350 million will be invested in four venture capital funds-of-funds managers under the renewed Venture Capital Catalyst Initiative (VCCI)…READ MORE

Technician, Process Development

Avivo Biomedical Inc. is seeking a highly motivated Technician to join the Process Development and Analytic team at Avivo. In this capacity, the Technician will support the development of upstream and downstream processes, as well as impurity assay development to support the ongoing development of our bacterial-produced enzyme-based product. These activities will involve a combination of protein biochemistry, enzymology and molecular biology. An ideal candidate must be able to take initiative in problem solving, prioritise assignments, work efficiently under time constraints, and work within teams and with minimum supervision.

LEARN MORE

Clinical Affairs Associate

The Clinical Affairs Associate is responsible for the development of Clinical Affairs infrastructure and program operations to ensure high quality and timeliness of clinical trials. Oversees operational aspects of all clinical studies and provides strategic direction for clinical trial operations through the direct line-management of the clinical research staff or Contract Research Organizations (CROs). The Clinical Affairs Associate is responsible for the development and implementation of clinical research and relevant regulatory processes and systems, for the core purpose of improving patient outcomes and saving lives globally.

LEARN MORE

Quality Manager

Sepset Biosciences Inc. seeks applications for an experienced quality assurance (QA) and regulatory affairs manager or consultant to help with the development and regulatory approval of Sepset’s medical diagnostic test for sepsis. The QA manager will report to the CSO and work closely with senior management and company employees to implement and maintain an eQMS system as well as ensure regulatory compliance. The individual will also make sure that company leadership is engaged in quality management practices and training to ensure that company objectives regarding quality and risk management are successfully met.

LEARN MORE

Incyte is a global biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and R&D drive Incyte’s business and its commitment to making a difference in the lives of patients through scientific discovery.

Visit Website

Augurex is a collaboration-driven, biomarker-evidence based biotechnology company. Privately held, we began our research programs in 2008 focused on the 14-3-3η protein, a novel biomarker involved in the joint damage process, with current applications in rheumatoid arthritis (RA). From this initial basic research, a portfolio of 14-3-3η-centric clinical programs emerged, that is unveiling the potential of this previously unfamiliar factor in autoimmunity, and transforming the management of RA.

Visit Website